Azoles therapeutic drug monitoring and fungal antimicrobial resistance in adults with Cystic Fibrosis
M. Di Paolo (London, United Kingdom), K. Dave (London, United Kingdom), A. Vijayasingam (London, United Kingdom), R. Sheth (London, United Kingdom), E. Luke (London, United Kingdom), A. Scourfield (London, United Kingdom), L. Nwankwo (London, United Kingdom), S. Schelenz (London, United Kingdom), J. Elborn (London, United Kingdom), D. Armstrong-James (London, United Kingdom), A. Shah (London, United Kingdom)
Source: International Congress 2018 – Latest developments in cystic fibrosis
Session: Latest developments in cystic fibrosis
Session type: Poster Discussion
Number: 3409
Disease area: Respiratory infections
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Di Paolo (London, United Kingdom), K. Dave (London, United Kingdom), A. Vijayasingam (London, United Kingdom), R. Sheth (London, United Kingdom), E. Luke (London, United Kingdom), A. Scourfield (London, United Kingdom), L. Nwankwo (London, United Kingdom), S. Schelenz (London, United Kingdom), J. Elborn (London, United Kingdom), D. Armstrong-James (London, United Kingdom), A. Shah (London, United Kingdom). Azoles therapeutic drug monitoring and fungal antimicrobial resistance in adults with Cystic Fibrosis. 3409
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you: